J
J. de Graaf
Researcher at Radboud University Nijmegen Medical Centre
Publications - 33
Citations - 1140
J. de Graaf is an academic researcher from Radboud University Nijmegen Medical Centre. The author has contributed to research in topics: Population & Cholesterol. The author has an hindex of 17, co-authored 33 publications receiving 1075 citations. Previous affiliations of J. de Graaf include University Medical Center Utrecht.
Papers
More filters
Journal ArticleDOI
Serum triglycerides and risk of cardiovascular disease.
TL;DR: The role of serum triglycerides in relation to the risk of cardiovascular disease is discussed and the view that triglyceride-rich lipoproteins are an independently associated risk factor is supported.
Journal ArticleDOI
Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment.
TL;DR: The results suggest an enhanced atherogenic potential of the small, dense LDLSubfractions within each LDL subfraction profile, which are less resistant to in vitro oxidation than the light, control LDL sub fractions.
Journal Article
Geriatric syndromes: medical misnomer or progress in geriatrics?
TL;DR: It is argued that the concept of geriatric syndromes is valuable as a theoretical frame, a directive for diagnostic analysis and as an educational tool in teaching geriatrics to medical students and trainees.
Journal ArticleDOI
A proposal to redefine familial combined hyperlipidaemia - Third workshop on FCHL held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation
Allan D. Sniderman,M. Castro Cabezas,J. Ribalta,Rafael Carmena,T.W.A. de Bruin,J. de Graaf,D. W. Erkelens,S.E. Humphries,Lluís Masana,José T. Real,P.J. Talmud,Marja-Riitta Taskinen +11 more
TL;DR: The hypothesis that the phenotype of FCHL might not be multiple but unitary – namely, hypertriglyceridaemic (hyperTg) hyperapoB is considered, which represents an evolution in diagnosis based on the advances in knowledge and technology that have occurred since the disorder was described.
Journal ArticleDOI
Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
Calin D. Popa,Mihai G. Netea,J. de Graaf,F.H.J. van den Hoogen,Trdj Radstake,Helga Toenhake-Dijkstra,P.L.C.M. van Riel,J.W.M. van der Meer,Anton F. H. Stalenhoef,Pilar Barrera +9 more
TL;DR: In patients with RA, chronic inflammation and its suppression during anti-TNF therapy have limited influence on plasma leptin concentrations, while significantly decreasing circulating adiponectin levels, which question the suggested key role of inflammatory markers in regulating adipocytokine patterns in RA.